Francis Torres, APRN
Family · Henderson, NVNPI 1659979052
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,194 of the $7,741 with a category attached, or 80.0%. 21 manufacturers reported payments, led by AstraZeneca at 29.5% of the total. 2025 is the largest year on record at $3,393, 3.0 times the $1,122 reported in 2021. Among family clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $52.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$1K
- Verona Pharma, Inc.$717
- United Therapeutics Corporation$640
- Actelion Pharmaceuticals US, Inc.$616
- GSK$422
- plus $2K from 15 others
What the payments were for
- Consulting fees$1,10514%
- Travel & lodging$290%
- Food & beverage$6,19480%
- Education$4135%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $2,284 |
| Sanofi | 18 | $1,283 |
| Verona Pharma, Inc. | 7 | $717 |
| United Therapeutics Corporation | 6 | $640 |
| Actelion Pharmaceuticals US, Inc. | 9 | $616 |
| GSK | 23 | $422 |
| Mylan Specialty L.p. | 2 | $246 |
| Jazz Pharmaceuticals Inc. | 5 | $226 |
| Electromed, Inc. | 4 | $214 |
| Baxter Healthcare | 4 | $204 |
| Boehringer Ingelheim | 3 | $200 |
| Amgen | 2 | $126 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Merck | 1 | $120 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $68 |
| Inogen, Inc. | 6 | $57 |
| Advanced Respiratory, Inc | 2 | $51 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $21 |
| Viatris Specialty LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,741 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 59 | $773,236 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 709 | $659,975 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 609 | $533,684 |
| Breo ElliptaFluticasone/Vilanterol | 205 | $126,719 |
| Spiriva RespimatTiotropium Bromide | 172 | $124,267 |
| SymbicortBudesonide/Formoterol Fumarate | 300 | $94,983 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 115 | $79,247 |
| Pirfenidone | 18 | $47,635 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $44,984 |
| Advair HfaFluticasone Propion/Salmeterol | 63 | $30,091 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 933 | $26,967 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 161 | $23,899 |
| Incruse ElliptaUmeclidinium Bromide | 46 | $16,935 |
| EliquisApixaban | 19 | $16,630 |
| Arnuity ElliptaFluticasone Furoate | 43 | $12,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $200 | $976,750346 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $422 | $860,8561,072 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,284 | $638,350922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.
Other family in Henderson
- Kristy SolisHenderson$23K
- Joseph LauHenderson$18K
- Judith YuHenderson$14K
- Daniel Sam AciertoHenderson$11K
- Reiko TapiaHenderson$10K
- Hollie TylerLas Vegas$118K
- John PhoenixLas Vegas$107K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Erin WilkinsonLas Vegas$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.